Analysts’ Updated EPS Estimates for November 15th (AMTX, ATNM, CELC, CRIS, HAE, KALA, PDSB, PPBT, SGMT, SLN)

Analysts’ updated eps estimates for Friday, November 15th:

Aemetis (NASDAQ:AMTX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $28.00 price target on the stock.

Actinium Pharmaceuticals (NYSE:ATNM) had its buy rating reissued by analysts at HC Wainwright. They currently have a $4.00 target price on the stock.

Celcuity (NASDAQ:CELC) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $27.00 target price on the stock.

Curis (NASDAQ:CRIS) had its buy rating reissued by analysts at HC Wainwright. They currently have a $20.00 target price on the stock.

Haemonetics (NYSE:HAE) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $112.00 price target on the stock.

KALA BIO (NASDAQ:KALA) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $15.00 target price on the stock.

PDS Biotechnology (NASDAQ:PDSB) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $21.00 price target on the stock.

Purple Biotech (NASDAQ:PPBT) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $33.00 target price on the stock.

Sagimet Biosciences (NASDAQ:SGMT) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $32.00 price target on the stock.

Silence Therapeutics (NASDAQ:SLN) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $75.00 target price on the stock.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its neutral rating reissued by analysts at HC Wainwright.

UBS Group AG started coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX). The firm issued a buy rating and a $21.00 price target on the stock.

Westport Fuel Systems (NASDAQ:WPRT) (TSE:WPRT) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $22.00 price target on the stock.

Y-mAbs Therapeutics (NASDAQ:YMAB) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $22.00 price target on the stock.